

Nectar Lifesciences Ltd.



Ref.: NLL/CS/2024- 418

October 21, 2024

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051
Symbol: NECLIFE

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001
Scrip Code: 532649

Sub: Intimation of Presentation of Business

Ref: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations 2015.

Dear Sir/ Madam,

Pursuant to captioned regulations, please find enclosed the presentation to be given to customers/ investors/ other stakeholders.

Kindly take the same on record and oblige.

Thanking you,

Yours faithfully,
For **Nectar Lifesciences Limited**

(Neha Vaishnav)
Company Secretary & Compliance Officer

Encl.: as above



Nectar Lifesciences LIMITED

A Cephalosporin Company

Cephalosporin Global Landscape

World Pharmaceutical Market: \$1.2tn

Antibiotics Market: \$100bn (Gen I-V)

Ceph Market: \$21bn (Gen I-V)


\$16bn

Nectar Lifesciences
Addressable Market

ABOUT THE COMPANY



Geography & Locations



Landmark	Location	Activity
Corporate HQ	Chandigarh	Corporate Functions Global <ul style="list-style-type: none"> • Marketing & BD • Finance & Accounting • Supply chain • Secretarial & Legal
Unit 1	Derabassi, Punjab	<i>Oral & Sterile Cephalosporin APIs</i>
Unit 2	Derabassi, Punjab	<i>Oral & Sterile Cephalosporin APIs</i>
Formulation (Unit 6)	Barotiwala Himachal Pradesh	<i>Cephalosporin FDFs - Oral & Injectables</i>
EHGC (Unit 7)	Barotiwala Himachal Pradesh	<i>Empty Hard Gelatin Capsule Manufacturing</i>

Our Strength

Well equipped to scale and capture a larger market share

**Global
Leader in
Cephalosporin API
Products**

**120 Acre API
campus** One of
the largest in the
world **11 plants**
Some dedicated,
others Multipurpose

**44 DMFs
filed, 9 CEPs
& 4 MAs
approved,
15 ANDA
filings**

**Competitive
Advantages
and
High Barriers
to Entry**

**Established
Relationships
with Marquee
Customers**

NLL has state-of-the-art facilities with leading global capabilities

Description	API Manufacturing		Formulations
	Unit 1	Unit 2	Unit 6
Activities	<ul style="list-style-type: none"> Predominantly caters to domestic and less regulated markets Sterile and non sterile cephalosporins Diversified lyophilized range of products with substantial capabilities 	<ul style="list-style-type: none"> Caters to semi regulated and highly regulated market 	<ul style="list-style-type: none"> Production of Finished Dosage Formulations
Products	<ul style="list-style-type: none"> 9 Sterile APIs 1 Oral API 	<ul style="list-style-type: none"> 6 Sterile APIs 6 Oral APIs 	<ul style="list-style-type: none"> Tablets Dry Syrups Granules Sterile Powders and Injectables
Location	Derabassi, Punjab		Baddi, Himachal Pradesh
Land Area (m ²)	36,423	1,77,816	20,230
Facilities	<ul style="list-style-type: none"> 11 Manufacturing facilities spread across Unit 1 and Unit 2 Unit 2 has a combination of Dedicated and MPP API manufacturing blocks Capability of expanding into new APIs of Brazil, Mexico, Japan, Korea, China for 15 APIs in MPPs Capex required to build another dedicated MPP Unit 2 has one of Asia's best sterile facilities with the least human intervention 12MW Power Plant (Two 6MW plants) 		<ul style="list-style-type: none"> Minimum human intervention High barriers to entry because of the Cross Contamination Process
Market Coverage	<ul style="list-style-type: none"> Caters to both domestic and export markets Exports to 40 countries More than 200 customers 		<ul style="list-style-type: none"> Exports single dosage forms Exports to 35 countries More than 40 customers
Production Capacities (Annual)	<ul style="list-style-type: none"> In Excess of 2000 MTs 		<ul style="list-style-type: none"> Tablets: 180 mn Capsules: 180mn Dry Syrups: 10.5mn Sterile Powder Injectables: 24mn Granules: 3,000kg



Manufacturing Capacities API

Derabassi Unit-1 & Unit-2 (API)

Oral

Cefixime Trihydrate

Cefpodoxime Proxetil

Cefuroxime Axetil (Amorphous)

Cefdinir

Ceftibuten

Sterile

Ceftriaxone Sodium Sterile

Cefotaxime Sodium Sterile

Cefuroxime Sodium Sterile

Ceftazidime for Injection

Cefipime HCL + Arginine

Cephalothin Sodium Sterile

Cefoperzone Sodium Sterile

Meropenem For Injection

Chloramphenicol Sodium Succinate Sterile

Cefazoline Sodium Sterile

Piperacillin Sodium+Tazobactam Sodium

Tazobactam Sodium Sterile


Unit 2





Nectar Lifesciences API Leadership

Oral Cephalosporins



Sterile Cephalosporins



- NLL has leading global capacities in Cefixime, Cefuroxime Axetil Amorphous, Cefuroxime Axetil Crystalline, Cefotaxime Sodium, and Ceftriaxone Sodium
- NLL is the world's leading producer of Cefixime Trihydrate, Cefuroxime Axetil, Cefpodoxime Proxetil and Sterile APIs
- All of NLL's plants can be converted to multi-purpose plants based on product basket requirement



API Manufacturing Unit

- Two units with total of 120 Acre Land cover consisting over 13 manufacturing facilities with combination of 3 Sterile and 1 Oral API Blocks in First unit and 2 Sterile and 7 Oral API Blocks in second Unit
- Plant has total combined Oral-Sterile capacity of 1300 MT and 816 MT for Sterile
- Global Approvals







FINISHED DOSAGE FACILITY

- Facility spread over 5 Acres of Land in Baddi district of Himachal Pradesh
- Minimum Human intervention
- High barriers to entry because of cross contamination process
- Exports to 35 countries and over 40 customers worldwide



Pharmacy and
Poisons Board



Safe Drugs Save Lives



EUROPEAN UNION
GMP

PORTUGAL



infarmed

Autoridade Nacional do Medicamento
e Produtos de Saúde I.P.



BRAZIL



OGYÉI

Országos Gyógyszerészeti
és Élelmezés-egészségügyi Intézet



Tanzania Medicines & Medical Devices Authority


Statement of Financial Results for the Quarter ended 30.06.2024 (Rs in Lacs)

S. No.	Particulars	Standalone			
		Quarter Ended			Year Ended
		30-Jun-24	31-Mar-24	30-Jun-23	31-Mar-24
		Unaudited	Audited	Unaudited	Audited
I	Income from Operations				
	Sales	41,750.91	51,168.41	45,100.27	1,92,583.19
	Less: GST Recovered	5,866.21	7,183.66	5,688.64	24,174.62
	Revenue from Operations	35,884.70	43,984.75	39,411.63	1,68,408.57
	Other operating Income	45.27	152.68	0.63	154.56
II	Other Income	55.08	146.84	47.31	1,303.00
III	Total Income (I + II)	35,985.05	44,284.27	39,459.57	1,69,866.13
IV	Expenses				
	(a) Cost of Materials consumed	29,698.35	36,031.73	28,365.27	1,24,244.99
	(b) Purchase of Stock in Trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5,964.12)	(5,239.39)	(448.52)	(4,020.82)
	(d) Employee benefits expense	2,398.66	2,394.29	1,879.62	8,467.08
	(e) Finance costs	1,997.68	2,415.95	1,762.25	8,714.17
	(f) Depreciation and amortisation expense	1,546.03	1,470.01	1,533.25	6,071.84
	(g) Other expenses	5,816.74	6,099.72	6,061.86	24,561.27
	Total Expenses (IV)	35,493.34	43,172.31	39,153.73	1,68,038.53
V	Profit before exceptional items and tax (III- IV)	491.71	1,111.96	305.84	1,827.60
VI	Exceptional Items	-	-	-	-
VII	Profit from ordinary activities before tax (V - VI)	491.71	1,111.96	305.84	1,827.60
VIII	Tax Expense				
	Current Tax	-	-	-	-
	Deferred Tax	194.80	1,052.05	123.80	1,327.43
IX	Profit for the period from continuing operations (VII-VIII)	296.91	59.91	182.04	500.17
	Other Comprehensive Income				
	Items that will not be reclassified subsequently to profit or loss				
	Remeasurement of the net defined benefit liability/asset (Net of Tax)		(34.19)	-	(34.19)
	Items that will be reclassified subsequently to profit or loss				
	Foreign Exchange Translation Reserve (Net of Tax)		-	-	-
	Total Other Comprehensive Income, (Net of Tax)		(34.19)	-	(34.19)
	Total Comprehensive Income for the period	296.91	25.72	182.04	465.98
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up)				
	a) Basic (In Rs.) - After Exceptional Item	0.13	0.03	0.08	0.22
	b) Basic (In Rs.) - Before Exceptional Item	0.13	0.03	0.08	0.22
	c) Diluted (In Rs.) - After Exceptional Item	0.13	0.03	0.08	0.22
	d) Diluted (In Rs.) - Before Exceptional Item	0.13	0.03	0.08	0.22

DEEPAK JINDAL & CO
 CHARTERED
 ACCOUNTANTS
 FRN 023023N
 CHANDIGARH



Nectar Lifescience's Global Reach



THANK YOU

